AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8350219 — intervention group
Group type: COMPARATOR
Intervention: Placebo (final content, 6.7 mg/L)
Number of subjects: 52
Study 3521277 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen (250 mg twice daily)
Number of subjects: 11
Study 3521277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3521277 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 11
Study 3521277 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen and Placebo
Number of subjects: 11
Study 30015064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg daily + P2Y12 inhibitor
Number of subjects: 0
Study 30015064 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily + P2Y12 inhibitor + aspirin
Number of subjects: 0
Study 30015064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 110 mg twice daily + P2Y12 inhibitor
Number of subjects: 0
Study 30015064 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg twice daily + P2Y12 inhibitor
Number of subjects: 0
Study 30015064 — intervention group
Group type: COMPARATOR
Intervention: VKA-based triple therapy
Number of subjects: 0
Study 27177859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' use of acceptance coping
Number of subjects: 275
Study 27177859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' use of emotional support coping
Number of subjects: 275
Study 27177859 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients reporting primary goal of treatment as 'cure my cancer'
Number of subjects: 275
Study 27177859 — intervention group
Group type: COMPARATOR
Intervention: FCs reporting depression
Number of subjects: 275
Study 27177859 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting depression
Number of subjects: 275
Study 27177859 — intervention group
Group type: COMPARATOR
Intervention: FCs reporting anxiety
Number of subjects: 275
Study 27177859 — intervention group
Group type: COMPARATOR
Intervention: Patients reporting anxiety
Number of subjects: 275
Study 23885105 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg
Number of subjects: 155
Study 23885105 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 250 mg
Number of subjects: 155
Study 23885105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 23885105 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix (both dosages)
Number of subjects: 155
Study 22919982 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light phototherapy using the Siriraj Phototherapy Lamp with 6 special blue fluorescent tubes
Number of subjects: 40
Study 22919982 — intervention group
Group type: COMPARATOR
Intervention: Light-emitting diodes (LEDs) phototherapy using the Bilitron 3006 with 5 super LEDs
Number of subjects: 40
Study 22919982 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-light phototherapy
Number of subjects: 40
Study 19696753 — intervention group
Group type: EXPERIMENTAL
Intervention: Modest energy deficit diet for 8 weeks (study A)
Number of subjects: 0
Study 19696753 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy liquid diet for 6 weeks (study B)
Number of subjects: 0
Study 19696753 — intervention group
Group type: EXPERIMENTAL
Intervention: QMR measurement
Number of subjects: 0
Study 18383972 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher oxygen concentration
Number of subjects: 1661
Study 16280742 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA assisted TUR
Number of subjects: 115
Study 16280742 — intervention group
Group type: COMPARATOR
Intervention: Standard white light TUR
Number of subjects: 115
Study 12090980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 4% sodium cromoglicate spray
Number of subjects: 290
Study 12090980 — intervention group
Group type: COMPARATOR
Intervention: Intranasal normal saline spray
Number of subjects: 290
Study 10369155 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital partner death
Number of subjects: 2
Study 10369155 — intervention group
Group type: COMPARATOR
Intervention: Marital partner myocardial infarction
Number of subjects: 2
Study 10369155 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous psychiatric consultation history
Number of subjects: 2
Study 10369155 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited individual coping skills
Number of subjects: 2
Study 8619016 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (0.5 mg) for 7 days
Number of subjects: 12
Study 8619016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2045293 — intervention group
Group type: COMPARATOR
Intervention: 67.2 Gy
Number of subjects: 447
Study 2045293 — intervention group
Group type: EXPERIMENTAL
Intervention: 72.0 Gy
Number of subjects: 447
Study 2045293 — intervention group
Group type: EXPERIMENTAL
Intervention: 76.8 Gy
Number of subjects: 447
Study 2045293 — intervention group
Group type: EXPERIMENTAL
Intervention: 81.6 Gy
Number of subjects: 447
Study 2045293 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfraction interval ≤ 4.5 hours
Number of subjects: 447
Study 2045293 — intervention group
Group type: EXPERIMENTAL
Intervention: Interfraction interval > 4.5 hours
Number of subjects: 447
Study 2045293 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 447
Study 6119168 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxatomide (2 mg/kg by mouth)
Number of subjects: 8
Study 6119168 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate powder (20 mg by inhalation)
Number of subjects: 8
Study 6119168 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo preparations
Number of subjects: 8
Study 31129603 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes with nicotine (ECwN) plus placebo tablets of varenicline
Number of subjects: 0
Study 31129603 — intervention group
Group type: COMPARATOR
Intervention: Electronic cigarettes without nicotine (ECwoN) plus placebo tablets of varenicline
Number of subjects: 0
Study 31129603 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic cigarettes without nicotine (ECwoN) plus 0.5 mg varenicline tablets
Number of subjects: 0
Study 31129603 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 0
Study 30235712 — intervention group
Group type: EXPERIMENTAL
Intervention: 5, 10, 15, 20, and 25 μg epidural sufentanil as an adjuvant with 10 mL of 0.65% ropivacaine
Number of subjects: 100
Study 26921890 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-specific education (video and written information about the medication prescribed)
Number of subjects: 100
Study 26921890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication-specific education)
Number of subjects: 100
Study 26921890 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication-specific education
Number of subjects: 100
Study 24508294 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation for 3 months
Number of subjects: 59
Study 22180217 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-delivered doxycycline microspheres with scaling and root planing
Number of subjects: 20
Study 22180217 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (Control)
Number of subjects: 20
Study 22180217 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally-delivered doxycycline microspheres
Number of subjects: 20
Study 20675354 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based natural mentoring relationships
Number of subjects: 3320
Study 17539693 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drug regimens that do not adversely affect major risk factors for CVD
Number of subjects: 0
Study 17539693 — intervention group
Group type: COMPARATOR
Intervention: Patients with schizophrenia
Number of subjects: 0
Study 17539693 — intervention group
Group type: COMPARATOR
Intervention: General population
Number of subjects: 0
Study 16111947 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 209
Study 16111947 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 209
Study 12115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple combination of methotrexate (MTX), hydroxychloroquine (HCQ), and sulfasalazine (SSZ)
Number of subjects: 171
Study 12115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and hydroxychloroquine (HCQ)
Number of subjects: 171
Study 12115219 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) and sulfasalazine (SSZ)
Number of subjects: 171
Study 10195337 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment with neuroleptics
Number of subjects: 30
Study 10195337 — intervention group
Group type: COMPARATOR
Intervention: Unmedicated schizophrenic patients
Number of subjects: 30
Study 10195337 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 30
Study 8645833 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1-g dose)
Number of subjects: 784
Study 2138532 — intervention group
Group type: EXPERIMENTAL
Intervention: GR 38032F (16 mg orally thrice daily)
Number of subjects: 39
Study 2138532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 2138532 — intervention group
Group type: EXPERIMENTAL
Intervention: GR 38032F
Number of subjects: 39
Study 6118250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg b.i.d. orally for 3 days)
Number of subjects: 34
Study 6118250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (7-day medication)
Number of subjects: 34
Study 6118250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 29043507 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration anesthesia via pressure syringe (P-INF)
Number of subjects: 101
Study 29043507 — intervention group
Group type: COMPARATOR
Intervention: Inferior alveolar nerve block anesthesia (IANB)
Number of subjects: 101
Study 27636542 — intervention group
Group type: EXPERIMENTAL
Intervention: Synriam plus praziquantel
Number of subjects: 128
Study 27636542 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 128
Study 27636542 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxidectin
Number of subjects: 128
Study 27636542 — intervention group
Group type: EXPERIMENTAL
Intervention: Synriam
Number of subjects: 128
Study 24476082 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (i.m.) urinary hCG injection
Number of subjects: 22
Study 24476082 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous (s.c.) recombinant hCG injection
Number of subjects: 22
Study 24476082 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG injection (both i.m. and s.c.)
Number of subjects: 22
Study 24476082 — intervention group
Group type: COMPARATOR
Intervention: hCG injection (s.c.)
Number of subjects: 22
Study 22289158 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent auditory cues
Number of subjects: 0
Study 22289158 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent auditory cues
Number of subjects: 0
Study 20385444 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 524
Study 20385444 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (reference material)
Number of subjects: 524
Study 18684076 — intervention group
Group type: EXPERIMENTAL
Intervention: Japanese acupuncture treatment
Number of subjects: 7
Study 18684076 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture treatment
Number of subjects: 7
Study 15999118 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg finasteride/day for 4 weeks prior to surgery
Number of subjects: 40
Study 15999118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no finasteride treatment)
Number of subjects: 40
Study 14600543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (50 mg.d(-1)) and beta-carotene (20 mg.d(-1)) in subjects with heavy exercise at leisure
Number of subjects: 14401
Study 14600543 — intervention group
Group type: COMPARATOR
Intervention: Placebo in subjects with heavy exercise at leisure
Number of subjects: 14401
Study 14600543 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity at work and leisure
Number of subjects: 14401
Study 14600543 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E and beta-carotene in subjects with physically load-bearing jobs
Number of subjects: 14401
Study 11858450 — intervention group
Group type: EXPERIMENTAL
Intervention: APN care only
Number of subjects: 140
Study 11858450 — intervention group
Group type: COMPARATOR
Intervention: No nursing care
Number of subjects: 140
Study 11858450 — intervention group
Group type: COMPARATOR
Intervention: Registered nurse (RN) care only
Number of subjects: 140
Study 11858450 — intervention group
Group type: COMPARATOR
Intervention: Both RN and APN care
Number of subjects: 140
Study 9109467 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American men
Number of subjects: 332544
Study 9109467 — intervention group
Group type: COMPARATOR
Intervention: White men
Number of subjects: 332544
Study 9109467 — intervention group
Group type: COMPARATOR
Intervention: African-American men compared to white men
Number of subjects: 332544
Study 9109467 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive ESRD
Number of subjects: 332544
Study 1460451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg oral dose
Number of subjects: 22
Study 1460451 — intervention group
Group type: COMPARATOR
Intervention: Terconazole 80 mg vaginal suppository daily for 3 days
Number of subjects: 22
Study 3913875 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 92
Study 3913875 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study 30295544 — intervention group
Group type: EXPERIMENTAL
Intervention: Snowflake MultiTeach (MT)
Number of subjects: 32
Study 30295544 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond Touch Table (DTT)
Number of subjects: 32
Study 30295544 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 32
Study 29342844 — intervention group
Group type: EXPERIMENTAL
Intervention: Short vacation in a hotel outside usual environment (n = 20)
Number of subjects: 40
Study 29342844 — intervention group
Group type: COMPARATOR
Intervention: Vacation at home (control group, n = 20)
Number of subjects: 40
Study 26823269 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention with written stepped-dose reduction (SIW)
Number of subjects: 532
Study 26823269 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured intervention with stepped-dose reduction and follow-up visits (SIF)
Number of subjects: 532
Study 26823269 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 532
Study 26823269 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 532
Study 24063257 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet rich in kernel-based barley products, brown beans and chickpeas (D1)
Number of subjects: 46
Study 24063257 — intervention group
Group type: COMPARATOR
Intervention: Control diet (D2)
Number of subjects: 46
Study 22934594 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Large Balloon Dilation (EPLBD)
Number of subjects: 83
Study 22934594 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 83
Study 21122660 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin 10/20 mg
Number of subjects: 112
Study 21122660 — intervention group
Group type: COMPARATOR
Intervention: simvastatin 40 mg
Number of subjects: 112
Study 18285431 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention (practice of functional gait activities in community environments)
Number of subjects: 30
Study 18285431 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based physiotherapy (Motor Relearning approach)
Number of subjects: 30
Study 18285431 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention
Number of subjects: 30
Study 15923574 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients receiving any cancer treatment
Number of subjects: 1505
Study 15923574 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly patients having a clinical trial discussion
Number of subjects: 1505
Study 12917169 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital stereoscopic fundus images
Number of subjects: 91
Study 12917169 — intervention group
Group type: COMPARATOR
Intervention: 35‐mm film
Number of subjects: 91
Study 12080674 — intervention group
Group type: EXPERIMENTAL
Intervention: Nao Yi-an (NYA) granule
Number of subjects: 38
Study 12080674 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (WM)
Number of subjects: 38
Study 8929750 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium diclofenac suspension (Flogan, Merck, 7ml, 105 mg) after food intake (FOOD phase)
Number of subjects: 13
Study 8929750 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium diclofenac suspension (Flogan, Merck, 7ml, 105 mg) after gastric acid secretion blockade (OME phase)
Number of subjects: 13
Study 8929750 — intervention group
Group type: COMPARATOR
Intervention: Placebo phase (PLA)
Number of subjects: 13
Study 1754989 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dose of dexamethasone (11.00 p.m.)
Number of subjects: 6
Study 1754989 — intervention group
Group type: COMPARATOR
Intervention: Morning dose of dexamethasone (08.00 a.m.)
Number of subjects: 6
Study 6500633 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential hypertension cases (n=33)
Number of subjects: 33
Study 6500633 — intervention group
Group type: COMPARATOR
Intervention: Normotensive control subjects (n=30)
Number of subjects: 33
Study 31760207 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cupping therapy (15 minutes, bilaterally at points BL23, BL24, BL25)
Number of subjects: 0
Study 31760207 — intervention group
Group type: COMPARATOR
Intervention: Placebo cupping therapy
Number of subjects: 0
Study 30180279 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive‐existential intervention for fear of cancer recurrence (FCR)
Number of subjects: 106
Study 25800460 — intervention group
Group type: EXPERIMENTAL
Intervention: Community singing program
Number of subjects: 131
Study 26248442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 157
Study 26248442 — intervention group
Group type: COMPARATOR
Intervention: Masking Therapy (Control)
Number of subjects: 157
Study 22364477 — intervention group
Group type: EXPERIMENTAL
Intervention: Theatre in education method (Group A, n = 42)
Number of subjects: 129
Study 22364477 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patients (Group B, n = 44)
Number of subjects: 129
Study 22364477 — intervention group
Group type: EXPERIMENTAL
Intervention: Role-play (Group C, n = 43)
Number of subjects: 129
Study 22364477 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 129
Study 20395225 — intervention group
Group type: EXPERIMENTAL
Intervention: Reporting suspected child maltreatment training
Number of subjects: 55
Study 20395225 — intervention group
Group type: COMPARATOR
Intervention: Learning to be sensitive to ethnicity
Number of subjects: 55
Study 22304889 — intervention group
Group type: EXPERIMENTAL
Intervention: CS only
Number of subjects: 104
Study 22304889 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent CS-US pairings
Number of subjects: 104
Study 22304889 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaired CS and US presentations
Number of subjects: 104
Study 22304889 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpaired 'discrimination' contingency with exteroceptive discrimination cue
Number of subjects: 104
Study 15943568 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg hydroxyurea
Number of subjects: 115
Study 15943568 — intervention group
Group type: COMPARATOR
Intervention: 800-900 mg hydroxyurea
Number of subjects: 115
Study 12183784 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training (5 times/week for 15 minutes)
Number of subjects: 40
Study 12183784 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapist-supervised exercises (30 sessions on average)
Number of subjects: 40
Study 12183784 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-training
Number of subjects: 40
Study 10485504 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg/d
Number of subjects: 251
Study 10485504 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 40 mg/d
Number of subjects: 251
Study 10485504 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg/d
Number of subjects: 251
Study 10485504 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg/d
Number of subjects: 251
Study 10485504 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 15 mg
Number of subjects: 251
Study 10485504 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg
Number of subjects: 251
Study 10485504 — intervention group
Group type: COMPARATOR
Intervention: omeprazole 20 mg
Number of subjects: 251
Study 10485504 — intervention group
Group type: EXPERIMENTAL
Intervention: lansoprazole and omeprazole
Number of subjects: 251
Study 8684201 — intervention group
Group type: EXPERIMENTAL
Intervention: Left dorsolateral prefrontal cortex rTMS
Number of subjects: 17
Study 8684201 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 17
Study 8684201 — intervention group
Group type: COMPARATOR
Intervention: Stimulation of different cortical areas
Number of subjects: 17
Study 1929762 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine hydrochloride substitution for 2 months
Number of subjects: 26
Study 1929762 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine therapy (nonsubstituted group)
Number of subjects: 26
Study 7037983 — intervention group
Group type: EXPERIMENTAL
Intervention: Live RSV vaccine
Number of subjects: 510
Study 7037983 — intervention group
Group type: COMPARATOR
Intervention: Placebo vaccine
Number of subjects: 510
Study 30301662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline alone (group HTS)
Number of subjects: 10
Study 30301662 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline and hydroxyethyl starch (HES) (group HTS/HES)
Number of subjects: 10
Study 30301662 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HTS and HTS/HES)
Number of subjects: 10